Clinical trials: COVID-19 Immunization
Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue
Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome
Some people report persistent health problems after receiving the COVID-19 vaccine. These symptoms persist well beyond typical short-term vaccine side effects and are not attributable to any other known medical conditions.
- Trial name
- CLEAR (NCT07400848)
- Testing
- Blood sampling and analysis, The continuous Reactive Hyperemia Index (InRHI) measured by EndoPAT
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bern
COVID-19
Message Encouraging Vaccination in Preparation for the Holidays
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned.
- Trial name
- NCT05612360
- Testing
- COVID Booster text messages
- Where
- United States
- Volunteers
- 520,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
COVID-19
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
This is a randomized, double-blind, active-controlled Phase Ⅲ clinical trial, as well as an immuno-bridging clinical trial by parallel testing previous serum after primary immunization of COVID-19 vaccine (Vero cell), inactivated…
- Trial name
- NCT05381350
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Where
- China
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination
Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and…
- Trial name
- NCT04417335
- Testing
- BCG vaccine
- Where
- 2 sites in Netherlands
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Autoimmune State, SARS-CoV-2 Infection
Security Efficacy COVID-19 Vaccination
Preliminary data support a possible molecular mimicry between SARS-CoV-2 and autologous components. This suggests the occurrence of autoimmunity during COVID-19. Consistently, autoimmunity may occur after SARS-CoV2 vaccination.
- Trial name
- SECVAX (NCT05743361)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Preference, Patient
Preferences of Vaccination for COVID-19 Among University Students and Staff: A Discrete Choice Experiment
From March 2021, COVID-19 vaccines have been made available to Hong Kong residents, first to priority groups including healthcare professionals and the elderly, and later to all adults and adolescents.
- Trial name
- NCT05150769
- Where
- Hong Kong
- Volunteers
- 3,423 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Vitamin d Deficiency, COVID-19
Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl
The aim of this observational retrospective study is to evaluate the effect of supplementation with cholecalciferol D3 in reducing the risk of: occurence of Long COVID syndrome after acute COVID-19 illness occurence of SARS-CoV-2…
- Conditions
- Vitamin d Deficiency, COVID-19, Long COVID
- Trial name
- LONGVITAVAX2 (NCT06452082)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Vaccine Refusal, COVID-19
Exploring the Effect of Video Interventions on Intentions for Continued COVID-19 Vaccination
While COVID-19 vaccine uptake has generally been high in Canada, with 83.4% of the total population having received the first two doses (i.e., primary series), additional "booster" uptake has been slower, especially among young…
- Trial name
- NCT05808413
- Testing
- Informational Video, Altruistic Video, Individualistic Video
- Where
- Canada
- Volunteers
- 3,567 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
HIV Infections, SARS-CoV-2 Infection
COVID-19 Serology in People Living with HIV in Hong Kong
Immunodeficiency associated with human immunodeficiency virus (HIV) infection could predispose people living with HIV/AIDS (PLHA) to defective serological responses following infection or vaccination.
- Conditions
- HIV Infections, SARS-CoV-2 Infection, Vaccination; Infection
- Trial name
- NCT05028881
- Testing
- blood sampling
- Where
- China
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Chronic Kidney Diseases, COVID-19
COVID-19 Vaccine Boosters in Patients With CKD
This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease and dialysis patients with poor humoral…
- Trial name
- BOOST KIDNEY (NCT05022329)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 273 people
- Sponsor
- Sunnybrook Health Sciences Centre
COVID-19
Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)
This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote…
- Trial name
- REMOTE (NCT06776367)
- Testing
- Remote study participation and self-collection of specimens, Traditional clinical trial participation with clinician-collected specimens
- Where
- 16 sites in United States
- Volunteers
- 1,753 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Covid19
Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela
Randomized, double-blind, placebo controlled clinical trial of immunogenicity, safety and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.
- Trial name
- VENEZUELA (NCT04642339)
- Testing
- Gam-COVID-Vac
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
The level of neutralizing antibody was detected by using the constructed pseudovirus covid-19 variant at baseline , 1 month , 6 months and 12 months after primary vaccination, within 15 days after booster immunization at 12…
- Trial name
- NCT05087277
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
- Trial name
- NCT04591717
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Effect of Drug
Antenatal COVID 19 Vaccination and Pregnancy Outcomes
Effect of COVID 19 vaccinations on pregnancy outcomes must be clear and identified to detect their safty
- Trial name
- NCT05401825
- Testing
- pfizer, astrazeneca,moderna,sinofac
- Where
- Egypt
- Volunteers
- 162 people
- Sponsor
- Ain Shams University
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Obesity
Diet and COVID-19 Vaccination
Recently, obesity and excess visceral fat were shown to be major risk factors for the development of complications following Covid 19 infection.
- Trial name
- NCT05163743
- Testing
- Low Calorie Ketogenic Diet
- Where
- Italy
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca